BACILIERI, MAGDALENA
 Distribuzione geografica
Continente #
NA - Nord America 1.318
AS - Asia 481
EU - Europa 278
AF - Africa 133
SA - Sud America 113
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 5
Totale 2.349
Nazione #
US - Stati Uniti d'America 1.264
SG - Singapore 206
CN - Cina 95
BR - Brasile 67
HK - Hong Kong 46
DE - Germania 41
FI - Finlandia 33
VN - Vietnam 31
IT - Italia 24
NL - Olanda 22
FR - Francia 20
UA - Ucraina 14
EC - Ecuador 11
IE - Irlanda 10
MX - Messico 10
MZ - Mozambico 10
SE - Svezia 10
RU - Federazione Russa 9
AR - Argentina 8
GB - Regno Unito 8
KZ - Kazakistan 7
LV - Lettonia 7
TR - Turchia 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
BY - Bielorussia 6
CR - Costa Rica 6
DZ - Algeria 6
EE - Estonia 6
GA - Gabon 6
JM - Giamaica 6
MR - Mauritania 6
TN - Tunisia 6
UG - Uganda 6
UY - Uruguay 6
AM - Armenia 5
AU - Australia 5
DJ - Gibuti 5
JO - Giordania 5
LU - Lussemburgo 5
SO - Somalia 5
TJ - Tagikistan 5
BF - Burkina Faso 4
BG - Bulgaria 4
BJ - Benin 4
CG - Congo 4
CM - Camerun 4
CV - Capo Verde 4
CY - Cipro 4
GH - Ghana 4
GT - Guatemala 4
IR - Iran 4
IS - Islanda 4
JP - Giappone 4
KR - Corea 4
LC - Santa Lucia 4
ML - Mali 4
MU - Mauritius 4
NC - Nuova Caledonia 4
PF - Polinesia Francese 4
PL - Polonia 4
PY - Paraguay 4
RO - Romania 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AF - Afghanistan, Repubblica islamica di 3
AZ - Azerbaigian 3
BE - Belgio 3
BW - Botswana 3
CD - Congo 3
CO - Colombia 3
CW - ???statistics.table.value.countryCode.CW??? 3
DK - Danimarca 3
EG - Egitto 3
ES - Italia 3
GM - Gambi 3
GR - Grecia 3
HN - Honduras 3
ID - Indonesia 3
IN - India 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LY - Libia 3
MA - Marocco 3
MG - Madagascar 3
MN - Mongolia 3
PG - Papua Nuova Guinea 3
PK - Pakistan 3
RS - Serbia 3
YT - Mayotte 3
ZM - Zambia 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
BO - Bolivia 2
Totale 2.268
Città #
Fairfield 197
Singapore 144
Woodbridge 109
Ashburn 102
Chandler 86
Houston 85
Santa Clara 82
Cambridge 74
Jacksonville 67
Wilmington 66
Seattle 58
Hong Kong 44
Princeton 33
Ann Arbor 30
Boardman 25
Des Moines 23
San Diego 19
Beijing 15
Dong Ket 13
Munich 13
Helsinki 11
Columbus 9
Nanjing 9
Dublin 8
Ho Chi Minh City 8
Los Angeles 8
Maputo 8
Buffalo 6
Falls Church 6
Kampala 6
Nouakchott 6
Riga 6
Tallinn 6
Tianjin 6
Amman 5
Dushanbe 5
Libreville 5
Medford 5
Montevideo 5
Padova 5
San José 5
Turku 5
Vienna 5
Bamako 4
Brooklyn 4
Castries 4
Frankfurt am Main 4
Kingston 4
Ljubljana 4
Minsk 4
Nanchang 4
Noumea 4
Ouagadougou 4
Papeete 4
Praia 4
Quito 4
Tashkent 4
Tokyo 4
Treviso 4
Yenibosna 4
Yerevan 4
Accra 3
Baku 3
Chicago 3
Cotonou 3
Djibouti 3
Gaborone 3
Guayaquil 3
Hanoi 3
Hargeisa 3
Hebei 3
Jinan 3
Kinshasa 3
Lusaka 3
Luxembourg 3
Mexico City 3
Nicosia 3
Port Moresby 3
Reykjavik 3
Salvador 3
Shenyang 3
São Gonçalo 3
São Paulo 3
Tunis 3
Ulan Bator 3
Vientiane 3
Willemstad 3
Abu Dhabi 2
Almaty 2
Americana 2
Antakya 2
Antananarivo 2
Apia 2
Athens 2
Atlanta 2
Banjul 2
Beira 2
Biên Hòa 2
Blantyre 2
Boston 2
Totale 1.609
Nome #
Combining ligand-based and structure-based drug design in the virtual screening arena 188
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure -activity profile. 178
G protein-coupled receptors as challenging druggable targets: insights from in silico studies 174
Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: Design of new Gly/NMDA receptor antagonists as a key study 171
A Novel Generalized 3D-QSAR Model of Camptothecin Analogs 169
Fit-For-Purpose PD-L1 Biomarker Testing for Patient Selection in Immuno-Oncology: Guidelines for Clinical Laboratories from the Canadian Association of Pathologists-Association Canadienne des Pathologistes (CAP-ACP) 154
Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity 149
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2AAdenosine Receptor Antagonists 145
Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the Activity of Human A3 Adenosine Receptor Antagonists. 135
Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update 129
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A(2A) receptor 125
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 122
Prediction of the acqueous solvation free energy of organic compounds by using autocorrelation of molecular electrostatic potential surface properties combined with response surface analysis 120
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: a novel tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 108
The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: Application to a lead optimization of a human A(3) adenosine receptor antagonist 106
Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-beta 1 expression in mesangial cells: biochemical and structural considerations 99
Response Surface Analysis as aternative 3D-QSAR tool: human A3 adenosine receptor antagonists as a key study. 81
Totale 2.353
Categoria #
all - tutte 8.053
article - articoli 8.053
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.106


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021136 0 0 0 0 8 31 0 9 33 13 25 17
2021/2022257 12 37 32 20 4 11 18 28 5 8 33 49
2022/2023197 36 7 0 18 33 55 0 14 25 0 7 2
2023/202486 4 14 16 9 9 1 9 7 2 1 7 7
2024/2025456 0 75 18 27 87 16 12 30 10 15 69 97
2025/2026695 43 96 216 248 92 0 0 0 0 0 0 0
Totale 2.353